Marmo Group has a disciplined approach to business development that allows us to focus on early stage technologies from leading universities and hospitals. We essentially bridge the gap between innovation and commercialization. The intellectual property we license will have a working prototype and have demonstrated proof of concept.

We select medical devices with short regulatory paths and reimbursement codes. The commercial launch of these technologies will be within 2 to 3 years of licensing. We look for platform technologies that reduce costs while improving patient care and anticipate liquidity events within 3 to 5 years with returns in excess of 5x.

In addition, the companies we create focus on the following acute care
and pre-hospital markets:

	Critical Care
	Anesthesia/O.R.
	Emergency Medicine
	Interventional/Minimally Invasive Surgery
	Pulmonary
	Pediatric and Neonatal